Guangmai Medical, a Global Leader in Molecular Imaging, Files IPO Prospectus Following Strategic Investment Led by Shanghai Biomedical Fund
Recently, Guangmai Medical, a global leader in molecular medical imaging, completed a financing round worth hundreds of millions of yuan. This round was led by the Shanghai Biomedical Industry Fund, with follow-on investment from the SME Development Fund (Chengdu) Jiaozi Venture Capital Partnership (Limited Partnership), managed by Oriental Fortune Capital.
Shanghai Guangmai Medical Technology Co., Ltd. is dedicated to the original innovation and R&D of digital molecular imaging equipment, leveraging its profound expertise and continuous iteration in semiconductor detection technology to long lead the global frontier of molecular imaging technological innovation.In 2007, Guangmai Medical pioneered the application of cadmium zinc telluride (CZT) semiconductor detectors in the field of medical imaging., creating the world’s first dedicated cardiac digital single-photon emission computed tomography (SPECT) system, D-SPECT®, currently D-SPECT®Holds over half of the global market share in dedicated cardiac SPECT devices.In 2018, Spectrum Dynamics launched VERITON-CT, the first and only high-energy, full-ring digital SPECT/CT product capable of direct imaging of multiple radionuclides, including I-131, for the global market.®，The ability to efficiently perform imaging and dosimetry of in vivo radionuclide drugs has become an important tool in the diagnosis and treatment of nuclear medicine.
Digital Total-Body SPECT/CT VERITON-CT®(Left)Digital Cardiac-Dedicated System D-SPECT®(Right)
D-SPECT by Guangmai Medical®and VERITON-CT®All have obtained FDA, CE, and NMPA certifications, with domestic certification for the aforementioned products expected to be achieved by the end of 2024.Guangmai Medical has ushered SPECT/CT into the fully digital era, successfully increasing image clarity by 2–5 times and detection speed by 5–10 times, while reducing radiation dose to 1/4–1/2 of conventional levels. This advancement empowers physicians to “see” the data value hidden within molecular imaging, comprehensively enhancing the diagnosis and precision treatment of various diseases, including oncology, cardiovascular, neurological, and urological conditions, and has earned consistent recognition and acclaim from the international medical community.
Guangmai Medical currently holds more than 100 invention and utility model patents. Guangmai Medical has successfully installed over 600 units worldwide, with itsMajor clients include the Mayo Clinic (USA), Johns Hopkins Hospital (USA), Cedars-Sinai Medical Center (Los Angeles), NYU Langone Health (New York), Toronto General Hospital (Canada), Gustave Roussy Cancer Campus (France), Linköping University Hospital (Sweden), University Hospital Zurich (Switzerland), The University of Tokyo Hospital (Japan), Peking Union Medical College Hospital (China), and Zhongshan Hospital, Fudan University (China)., have all established long-term collaborative relationships in clinical practice and scientific research.
In 2021, Guangmai Medical established its group parent company and global production headquarters in Lingang, Shanghai, and officially commenced production in July 2022. This achievement realized the domestic manufacturing of high-end digital SPECT equipment, laying a solid foundation for filling the technological gap in China and supporting the sustained development of the domestic molecular imaging industry.
Liang Weibin, Partner at Shanghai Biomedical Fundstated: “Guangmai Medical is a global leader in high-end medical imaging equipment, boasting exceptional original innovation capabilities and profound technological expertise. As a global pioneer in technological innovation and commercialization within its product category, the company’s two core products have gained widespread recognition from top-tier medical institutions both domestically and internationally for their outstanding performance. We believe the company is well-positioned to further strengthen its supply chain system, expand into global markets, and continuously drive the launch of innovative products. Capitalizing on the global trend and opportunities of ‘integrated diagnosis and therapy,’ Guangmai Medical will fill the domestic gap in digital SPECT/CT technology, advancing nuclear medicine to benefit more patients.”
Li Xiaonan, Deputy General Manager of the Shanghai Management Headquarters and Partner at Oriental Fortune Capital“Against the backdrop of rapid development in the global nuclear medicine field, the widespread application of radiopharmaceutical therapies is driving robust growth in demand for SPECT equipment. Leveraging its profound expertise and technological innovations in molecular imaging, Guangmai Medical has emerged as a leading enterprise in high-end medical imaging devices worldwide. The company’s digital SPECT products deliver leapfrog performance improvements over traditional systems, opening new possibilities for innovative clinical diagnosis and treatment protocols. With the implementation of Guangmai Medical’s localization strategy in China, we believe its technologies and products are poised to play an even more significant role on the global stage. We look forward to collaborating with Guangmai Medical to jointly advance medical imaging technology and provide patients worldwide with more precise and efficient diagnostic and therapeutic experiences.”